Application of aspartic acid in preventing or treating obesity

Abstract

The invention discloses application of aspartic acid in preventing or treating obesity. The aspartic acid is L-aspartame, and the usage amount of the L-aspartame is 40-200 microns. The inventor finds that the L-aspartame has the effects of inhibiting adipogenesis, reducing triglyceride level in fat cells, effectively controlling the level of glucose, insulin and free fatty acid in vivo, reducing the content of total fat tissues and fat tissues at each part, and inhibiting fat cell maturation, so that the L-aspartame has potential medicinal value for effectively preventing or treating obesity.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of aspartic acid in preventing or treating obesity. Background technique [0002] The occurrence of obesity is due to the imbalance between energy intake and energy consumption in the body, resulting in excessive fat hyperplasia and abnormal accumulation. In recent years, obesity has become a major health problem worldwide. About 2.1 billion people in the world are overweight or obese. The incidence of overweight in adults is 28.1%, and the incidence of obesity is 5.2%. Related technical studies have shown that obesity may lead to various complications, such as non-alcoholic fatty liver disease (NAFLD), cardiovascular and cerebrovascular diseases, hypertension, type 2 diabetes (type 2diabetes, T2D), cancer etc., seriously endangering human health. [0003] In the related art, obesity treatment methods are very limited. At present, the treatment of obesity ...

AI Technical Summary

Problems solved by technology

Drugs that inhibit intestinal lipid absorption, such as intestinal lipase inhibitor orlistat, can reduce fat absorption by about 30%, but it is easy to affect the absorption of fat-soluble vitamins in patients, and there are adverse reactions in the gastrointestinal tract, which may lead to severe Liver damage; drugs that regulate the nerve center to suppress appetite, such as central appetite inhibitors phentermine / topiramate, naltrexone / bupropion hydrochloride all act on the hypothalamus appetite regulation pathway to reduce appetite, but there is a risk of addiction and central side effects; drugs that promote energy metabolism, such as peripheral appetite suppressant liraglutide, are relatively safe in vivo, but are expensive and require injection

In addition to marketed drugs, other obesity drug treatment strategies that have received wide attention include activating white adipose tissue browning, down-regulating sterol regulatory-element binding proteins (SREBPs), peroxisome proliferator-activated receptors Body γ (peroxisome proliferator-activated receptor γ, PPAR-γ) develops growth hormone releasing peptide (Ghrelin) inverse agonist, Bombesin receptor subtype 3 (bombesin receptor subtype-3, BRS-3) agonist, melanin concentrating hormone (melanin) concentrating hormone (MCH) antagonists, etc., but its safety and long-term efficacy still need to be further verified

Images